SCHEMBL5569661

SCHEMBL5569661

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C)c(Cl)cc3OCCN3CCCC3)cc2)ccn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 2/20 0.60
▸ MAPK14 Q16539 5/20 0.59
▸ RAF1 P04049 9/20 0.53
▸ KDR P35968 6/20 0.53
▸ EPHX2 P34913 4/20 0.53
▸ SRC P12931 3/20 0.53
▸ ABL1 P00519 3/20 0.53
▸ RET P07949 3/20 0.53
▸ EPHA2 P29317 3/20 0.53
▸ AURKB Q96GD4 3/20 0.53
▸ MAP3K20 Q9NYL2 3/20 0.53
▸ RIPK2 O43353 2/20 0.53
▸ ABCB11 O95342 2/20 0.53
▸ HTR1A P08908 2/20 0.53
▸ PDGFRB P09619 2/20 0.53
▸ ADORA3 P0DMS8 2/20 0.53
▸ KIT P10721 2/20 0.53
▸ FGFR1 P11362 2/20 0.53
▸ BRAF P15056 2/20 0.53
▸ PDGFRA P16234 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569561 0.93 GSK3B (0.58) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL5565553 0.93 GSK3B (0.58) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL5565578 0.92 RET (0.54) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL171401 0.90 DDR2 (0.55) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL14453602 0.90 GSK3B (0.76) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL13648366 0.89 GSK3B (0.48) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL14453662 0.89 MAPK14 (0.59) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL171224 0.88 DDR2 (0.49) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL13648405 0.88 GSK3B (0.47) GSK3BMAPK14RAF1KDREPHX2
SCHEMBL15575261 0.87 DDR2 (0.55) GSK3BMAPK14RAF1KDREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2007519653-A — — 2007-07-19 — — JP claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US claimed
EP-1730111-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GmbH (DE) 2006-12-13 — — EP claimed
WO-2005075425-A2 SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2005-08-18 — — WO claimed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed
US-20070161677-A1 Bisarylurea derivatives MERCK PATENT GMBH (DE) 2007-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161677-A1 Bisarylurea derivatives BRAF, RAF1, NRAS GSK3B 352/4885MAPK14 233/4885RAF1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback